相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An Antibody against the C-Terminal Domain of PCSK9 Lowers LDL Cholesterol Levels In Vivo
Felix Schiele et al.
JOURNAL OF MOLECULAR BIOLOGY (2014)
Annexin A2 Heterotetramer: Structure and Function
Alamelu Bharadwaj et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Multiple Roles of Annexin A2 in Post-Transcriptional Regulation of Gene Expression
Anni Vedeler et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2012)
The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway
Yascara Grisel Luna Saavedra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
The biology and therapeutic targeting of the proprotein convertases
Nabil G. Seidah et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
Nabil G. Seidah et al.
PLOS ONE (2012)
Genotoxic Agents Promote the Nuclear Accumulation of Annexin A2: Role of Annexin A2 in Mitigating DNA Damage
Patricia A. Madureira et al.
PLOS ONE (2012)
Annexin A2 and PSF proteins interact with p53 IRES and regulate translation of p53 mRNA
Arandkar Sharathchandra et al.
RNA BIOLOGY (2012)
Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
Anna Roubtsova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9
Rachid Essalmani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
Yan G. Ni et al.
JOURNAL OF LIPID RESEARCH (2011)
Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
Oystein L. Holla et al.
JOURNAL OF LIPID RESEARCH (2011)
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
Robert J. Konrad et al.
LIPIDS IN HEALTH AND DISEASE (2011)
Effects of the Prosegment and pH on the Activity of PCSK9 EVIDENCE FOR ADDITIONAL PROCESSING EVENTS
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
A new method for measurement of total plasma PCSK9: clinical applications
Genevieve Dubuc et al.
JOURNAL OF LIPID RESEARCH (2010)
Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain
Thea Bismo Strom et al.
MOLECULAR GENETICS AND METABOLISM (2010)
PCSK9 as a therapeutic target of dyslipidemia
Nabil G. Seidah
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
Hai Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation EVIDENCE FOR AN INTRACELLULAR ROUTE
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Berberine decreases PCSK9 expression in HepG2 cells
Jamie Cameron et al.
ATHEROSCLEROSIS (2008)
PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans
Thilina Dewpura et al.
FEBS JOURNAL (2008)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
Gaetan Mayer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Molecular basis for LDL receptor recognition by PCSK9
Hyock Joo Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
Da-Wei Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The p11/S100A10 Light Chain of Annexin A2 Is Dispensable for Annexin A2 Association to Endosomes and Functions in Endosomal Transport
Etienne Morel et al.
PLOS ONE (2007)
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Jun Li et al.
BIOCHEMICAL JOURNAL (2007)
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation
Timothy S. Fisher et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
Yue-Wei Qian et al.
JOURNAL OF LIPID RESEARCH (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nasha Nassoury et al.
TRAFFIC (2007)
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
David Cunningham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Annexin A2 recognises a specific region in the 3′-UTR of its cognate messenger RNA
Hanne Hollas et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2006)
The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
IK Kotowski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Annexin A2 binds to the localization signal in the 3 ' untranslated region of c-myc mRNA
I Mickleburgh et al.
FEBS JOURNAL (2005)
Annexin A2 is a novel RNA-binding protein
NR Filipenko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
SW Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Annexin II is associated with mRNAs which may constitute a distinct subpopulation
A Vedeler et al.
BIOCHEMICAL JOURNAL (2000)
Comparative characterization of two forms of recombinant human SPC1 secreted from Schneider 2 cells
JB Denault et al.
PROTEIN EXPRESSION AND PURIFICATION (2000)
分享论文
